Description

Icatibant represents a synthetic decapeptide developed as a selective bradykinin B2 receptor antagonist, designed to investigate inflammatory pathways and pain mechanisms in research applications. The compound demonstrates high binding affinity and selectivity for bradykinin B2 receptors, effectively blocking the actions of bradykinin and related kinins in biological systems. The peptide incorporates specific amino acid modifications designed to enhance receptor binding affinity and selectivity while providing resistance to enzymatic degradation. Icatibant functions as a competitive antagonist at bradykinin B2 receptors, preventing the binding and activation of endogenous bradykinin and thereby blocking downstream inflammatory signaling cascades. Research applications include investigation of inflammatory mechanisms, pain pathways, and the role of bradykinin signaling in various physiological and pathological processes. For research use only.